PORTLAND, Ore., Oct. 20, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:RXII), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that the Phase 1/2 clinical trial results from its lead asset, NeuVax™ (E75), were published this month in the journal Cancer, published by the American Cancer Society (article may be found at: http://onlinelibrary.wiley.com/doi/10.1002/cncr.26574/abstract).
